Home ›
Leukemia Trials ›
NCT05211570
AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
The primary objective is to define the safety and tolerability of AB8939 in patients with AML by determining the dose-limiting toxicities, the maximum tolerated dose, and the recommended dose for dose expansion study.
Trial Details
NCT ID NCT05211570
Phase PHASE1 / PHASE2
Sponsor AB Science
Status RECRUITING
Cancer Type Leukemia
Interventions
Locations (sample) Houston, Texas, United States|29.76328,-95.36327 Marseille, France|43.29695,5.38107 Athens, Greece|37.98376,23.72784 Alicante, Spain|38.34517,-0.48149 Cáceres, Spain|39.47649,-6.37224
Key Eligibility Criteria
Patients with documented diagnosis of acute myeloid leukemia (AML) based on the last version of the World Health Organization classification and el… Patients with documented diagnosis of refractory melyodisplastic syndrome in second or third line of treatment, and with high risk at prognosis bas… ECOG performance status ≤ 1 Patients are able to understand, sign, and date the written informed consent form at screening visit prior to any protocol-specific procedures
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Leukemia Trials on Trialify →